Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

February 12, 2013; 80 (7 Supplement) March 22,2013

Anti-Malarial Drug Artemisinin Extenuates Amyloidogenesis and Neuroinflammation in APPswe/PS1dE9 Transgenic Mice Via Inhibition of NF-κB and NLRP3 Inflammasome Activation (IN9-2.004)

Jian-Quan Shi, Jun Xu, Ying-dong Zhang, Chu-chu Zhang, Xiu-lan Sun
First published February 8, 2016,
Jian-Quan Shi
1Neurology Nanjing Medical University Affiliated Brain Hospital Nanjing China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Xu
2 Nanjing Medical University Affiliated Brain Hospital Nanjing China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying-dong Zhang
3Neurology Nanjing Medical University Affiliated Nanjing 1st Municipal Hosital Nanjing China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chu-chu Zhang
4Neurology Nanjing Medical University Affiliated Brain Hospital Nanjing China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiu-lan Sun
5Neuropharmocology Nanjing Medical University Nanjing China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Anti-Malarial Drug Artemisinin Extenuates Amyloidogenesis and Neuroinflammation in APPswe/PS1dE9 Transgenic Mice Via Inhibition of NF-κB and NLRP3 Inflammasome Activation (IN9-2.004)
Jian-Quan Shi, Jun Xu, Ying-dong Zhang, Chu-chu Zhang, Xiu-lan Sun
Neurology Feb 2013, 80 (7 Supplement) IN9-2.004;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE: To test if artemisinin, an anti-Malarial drug, can slow down the amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice and the mechamism will be investigated further.

BACKGROUND: Neuroinflammation is thought to be the key mechanism linked to Alzheimer's disease (AD) pathogenesis, which is deeply invovled in amyloid plaques, neurofibrillary tangles and microglia activation. Artemisinin has been reported to exert anti-inflammatory effects but the exact machanism need to clarified, and the effect of downregulation of amyloid deposition indicates the new direction for AD secondary prevention strategies.

DESIGN/METHODS: 5-month-old APPswe/PS1dE9 transgenic mice were used to evaluate the effects of artemisinin on AD pathogenesis, Five mice were injected with 40 mg/kg artemisinin in DMSO at the same time once daily, for continuous 30 days. The other five mice were injected with DMSO as control. Immunohistochemical staining, Western Blotting, ELISA were combined to evaluate the expression or levels of soluble and insoluble Aβ42, IL-6, TNF-α, IL-1β,LRP1, RAGE, APP carboxyl terminal, BACE1, PS1, Aph-1a, serine 536 phosphorylated NF-κB p65, NF-κB p65, IκB-α, serine 32 phosphorylated IκB-α, NALP3, Cleaved Caspase-1 (Asp297).

RESULTS: We found that artemisinin treatment can (1) decreased neuritic plaque burden; (2) didn't alter Aβ transport across the blood–brain barrier; (3) regulated APP processing via inhibiting β-secretase activity; (4) inhibited NF-κB activity and NALP3 inflammasome activation in APPswe/PS1dE9 double transgenic mice. The in vivo study clearly demonstrates that artemisinin has protective effects on AD pathlogy due to its effects on suppressing NF-κB activity and NALP3 inflammasome activation.

CONCLUSIONS: The in vivo study clearly demonstrates that artemisinin has protective effects on AD pathlogy due to its effects on suppressing NF-κB activity and NALP3 inflammasome activation. Furthermore, Our study suggests that artemisinin could be potent candidate in the secondary prevention drugs for AD.

Supported by: National Natural Science Foundation of China grant (30700248; 81271211), and Jiangsu Provincial Natural Science Foundation of Basic Research Plan (BK2009049). We thank Laboratory Animal Center of Nanjing First Hospital for breeding the animals and providing animal experimental facility.

Disclosure: Dr. Shi has nothing to disclose. Dr. Xu has nothing to disclose. Dr. Zhang has nothing to disclose. Dr. Zhang has nothing to disclose. Dr. Sun has nothing to disclose.

Friday, March 22 2013, 8:00 am-12:00 pm

  • Copyright © 2013 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (16)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise